RDHL
RedHill Biopharma Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IL
$0.39
−6.91%Oct 19, 2026, 12:00 UTC
RedHill Biopharma Ltd. received a $2.9 million National Cancer Institute grant to support clinical development of opaganib combined with CAR T-cell therapy for ultra-high-risk multiple myeloma.
Source:Sep 30, 2026, 20:05 UTC
RedHill Biopharma reported its first half 2026 financial results alongside operational highlights, including its reset portfolio of Rebyota and Clenpiq, which generated $37.5 million in 2025 net sales under Ferring Pharmaceuticals.
Source:Sep 2, 2026, 14:00 UTC
RedHill acquired global commercialization rights to Ferring's Rebyota and Clenpiq.
Source:Aug 31, 2026, 11:00 UTC
RedHill Biopharma divested its 70% stake in Talicia to Apotex for an $18 million upfront cash payment plus up to $35 million in potential milestone payments.
Jun 22, 2026, 20:10 UTC
RedHill Biopharma closed a private placement of ADSs and warrants for up to $19.4 million in gross proceeds.
Source:Jun 18, 2026, 12:00 UTC
RedHill Biopharma Ltd. announced a private placement of up to $19.4 million, with $6 million upfront and up to approximately $13.4 million from warrant exercises.
Source:Jun 9, 2026, 11:00 UTC
The FDA granted rare pediatric disease designation to RedHill's opaganib for neuroblastoma treatment.
Source:Jun 8, 2026, 11:00 UTC
RedHill Biopharma Ltd. launched enforcement of an $11 million New York Supreme Court final judgment against Kukbo.
Source: